Barclays
BPMC

Barclays’s Blueprint Medicines BPMC Stock Holding History

Barclays’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-95,300
Closed -$12.2M – 5497
2025
Q2 		$12.2M Buy
+95,300
New +$9.9M ﹤0.01% 1431
2024
Q3 		– Sell
-184,400
Closed -$19.9M – 5306
2024
Q2 		$19.9M Buy
184,400
+80,500
+77% +$8.06M 0.01% 937
2024
Q1 		$9.86M Buy
103,900
+59,300
+133% +$5.09M ﹤0.01% 1398
2023
Q4 		$4.11M Buy
+44,600
New +$2.89M ﹤0.01% 2282
2019
Q3 		– Sell
-39,200
Closed -$3.7M – 6720
2019
Q2 		$3.7M Buy
39,200
+38,000
+3,167% +$3.14M ﹤0.01% 2169
2019
Q1 		$96K Buy
+1,200
New +$88.7K ﹤0.01% 5382
2018
Q4 		– Sell
-30,000
Closed -$2.34M – 6947
2018
Q3 		$2.34M Buy
+30,000
New +$2.09M ﹤0.01% 2698

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's BPMC Position: Q3 2025 in Review

Barclays sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 1,556,918 shares — an estimated $200M sold.

Barclays first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $200M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Barclays reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 1,556,918 Blueprint Medicines shares in Q3 2025, an estimated $200M.
  • Barclays first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
  • Barclays's Blueprint Medicines position peaked at $200M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.